The Latest Cardiac and Vascular News
WAYNE, Penn.–(BUSINESS WIRE)–Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company’s commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His […]
PHOENIX, Feb. 20, 2025 /PRNewswire/ — Trinity Capital Inc. (NASDAQ: TRIN) (“Trinity Capital”), a leading alternative asset manager, today announced the commitment of $15 million in growth capital to Cagent Vascular Inc., a leading developer of serration technology for vessel dilation in…
WAYNE, Penn.–(BUSINESS WIRE)–Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the launch of its newest product, Serranator SL-PRO™ PTA Serration Balloon Catheter. “As an experienced Serranator operator, my team has grown accustomed to the benefits of Serration including great lumen gain, […]
WAYNE, Penn.–(BUSINESS WIRE)–Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the start of the POINT FORCE Registry, a post-market clinical follow-up study of the Serranator® PTA Serration Balloon Catheter. “What we endeavor to understand In POINT FORCE is the role Serranation can […]
WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular announced today that Brian Walsh has been named Chief Executive Officer by the Cagent Vascular Board of Directors. He has served as Chairman of the Board since March 2018 and will continue in this capacity. Mr. Walsh will succeed Carol Burns as CEO. “It is a […]
WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, today announced a Series C Financing close in excess of $30M. U.S. Venture Partners (USVP), led the round. Participation included new investor Blue Ridge Medical, LLC and existing investors, including Sectoral Asset Management. “We are pleased with […]
WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee (BTK) RECOIL study. This Core Lab-Adjudicated Recoil analysis, the first of its kind, evaluated vessel recoil in lesions treated with Serranator® verses Plain Old Balloon Angioplasty (POBA). The […]
WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular, the exclusive developer of Serration Angioplasty (Serranator®), announced the results of a comparative sub-analysis of the PRELUDE-Below-the-Knee (BTK) study versus Plain Old Balloon Angioplasty (POBA). The study was led by Dr. Marianne Brodmann (Radcliffe Cardiology, Graz, Austria). This sub-analysis compared their PRELUDE-BTK subset to a consecutive […]
WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular Inc., a developer of next generation angioplasty balloons using serration technology, announced the expansion of its product offering to include larger balloons to treat superficial femoral and popliteal arteries in the Above-the-Knee (ATK) segment. Cagent Vascular launched the Serranator® Below-the-Knee (BTK) product in January 2021. Since then, […]
WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular, a developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its PRELUDE-BTK Study at this year’s LINC Symposium on January 29th. The PRELUDE-BTK Study, was a prospective, single-arm, multi-center feasibility study to show the safety and efficacy of Serration Angioplasty. The […]
